BiondVax Pharmaceuticals Ltd. Stock Price, News & Analysis

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced the filing of a Form F-1 with the SEC for a firm commitment underwritten offering of American Depositary Shares (ADSs). This capital raise aims to support the development of its COVID-19 NanoAb inhaled therapy and expand its pipeline, including treatments for psoriasis and asthma. However, BiondVax received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity of $2,500,000, reporting only $1,277,000. The company has 45 days to submit a plan to regain compliance.

BiondVax Pharmaceuticals (Nasdaq: BVXV) announced progress in its collaboration with the Max Planck Institute and University Medical Center Göttingen to develop innovative alpaca-derived nanosized antibody (NanoAb) therapies. The team has successfully generated NanoAbs targeting IL-17A, IL-17F, and IL-13 aimed at treating psoriasis, psoriatic arthritis, and asthma. A preclinical study for an inhaled COVID-19 NanoAb therapy is set to begin soon, with potential clinical trials in 2023. BiondVax's strategy aims to capitalize on validated antibody targets, showcasing significant commercial potential.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its CEO, Amir Reichman, will attend the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. His pre-recorded presentation will also be available online. Investors can schedule one-on-one meetings with him and Chairman Mark Germain via the conference's scheduling platform. BiondVax specializes in developing innovative products for infectious diseases, having conducted eight clinical trials, including a Phase 3 trial involving 12,400 participants.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported financial results for Q2 2022, highlighting significant advances in its COVID-19 NanoAb program. R&D expenses surged to NIS 6.5 million ($1.85 million) from NIS 1.9 million YoY, reflecting ongoing drug development initiatives. The company plans to initiate a proof of concept study in September 2022. While the net loss increased to NIS 12.9 million ($3.7 million) from NIS 12.0 million YoY, cash reserves stood at NIS 39.5 million ($11.3 million), down from NIS 54.0 million at 2021 year-end.

BiondVax Pharmaceuticals (Nasdaq: BVXV) announced the formal approval from the European Investment Bank (EIB) to restructure its €24 million loan. Key terms include extending maturity to December 2027, deferring interest payments until then, and implementing a repayment plan with an initial payment of $900,000. Additionally, BiondVax will pay 3% of revenues exceeding €5 million as royalties to the EIB. This development supports BiondVax's strategy to advance its nanosized antibody (NanoAb) pipeline with collaboration partners in Germany.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced receiving supportive feedback from the Paul Ehrlich Institute (PEI) regarding its COVID-19 NanoAb therapy development. PEI's advice, a crucial step towards regulatory approval, endorses a combined Phase 1/2a clinical trial to assess safety and efficacy, significantly shortening the development timeline. BiondVax plans to commence this trial in 2023, following anticipated proof-of-concept studies. The NanoAb boasts advantages such as easy self-administration via inhalation and stability at higher temperatures.

BiondVax Pharmaceuticals Ltd. (BVXV) released its first quarter financial results for 2022, reporting total operating expenses of NIS 8.3 million ($2.6 million), up from NIS 6.8 million in Q1 2021. R&D expenses rose to NIS 3.65 million ($1.1 million), primarily driven by advancements in the NanoAb program targeting COVID-19. The company also presented successful in-vitro neutralization results against COVID-19 and Omicron. As of March 31, 2022, BiondVax had cash and equivalents of NIS 48.9 million ($15.4 million), a decrease from NIS 54.0 million at the end of 2021.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, in Miami, Florida. The presentation, led by Chairman Mark Germain at 9:30 AM ET, will highlight their innovative nanosized antibodies (NanoAbs), developed with the Max Planck Institute and University Medical Center Göttingen, targeting significant medical needs like COVID-19, asthma, and macular degeneration. Investors interested in meeting Mr. Germain can contact investor relations.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported significant advancements in its nanosized antibodies (NanoAbs) program at the Biomed conference in Tel Aviv. Highlights include successful technology transfer from the Max Planck Institute, enabling in-house production of a COVID-19 NanoAb with strong in-vitro neutralization capabilities. A new NanoAb targeting the Omicron variant has also shown effective neutralization in vitro. CEO Amir Reichman expressed optimism about leveraging these achievements for future NanoAb developments, positioning BiondVax strategically in addressing various unmet medical needs.